论文部分内容阅读
目的观察血管紧张素Ⅱ受体拮抗剂坎地沙坦与胰激肽原酶联合治疗糖尿病肾病治疗疗效。方法选择符合诊断标准的2型糖尿病肾病患者86例,在血糖控制基本正常的基础上随机分成2组,对照组40例患者给予常规降血糖及血管紧张素受体拮抗剂治疗,治疗组46例在此基础上加用胰激肽原酶治疗。结果治疗组经治疗后24h尿微量蛋白定量(UAE)有明显下降,与对照组相比差异有显著性统计学意义(P<0.05)。结论血管紧张素Ⅱ受体拮抗剂联合胰激肽原酶对早期糖尿病肾病有显著疗效,能消除或明显减少尿蛋白。可以延缓糖尿病肾病的发展,保护肾功能,安全有效,值得临床推广。
Objective To observe the therapeutic effect of candesartan and pancreatic kininogenase combined with angiotensin Ⅱ receptor antagonist in the treatment of diabetic nephropathy. Methods Eighty-six patients with type 2 diabetic nephropathy who met the diagnostic criteria were randomly divided into two groups on the basis of the normal and normal control of blood glucose. Forty patients in the control group were given conventional hypoglycemic and angiotensin receptor blocker therapy. 46 cases On this basis with the addition of pancreatic kallikrein treatment. Results The urinary microalbuminuria (UAE) in the treatment group decreased significantly after treatment, which was significantly different from the control group (P <0.05). Conclusion The combination of angiotensin Ⅱ receptor antagonist and pancreatic kallikrein has a significant effect on early diabetic nephropathy and can eliminate or significantly reduce urinary protein. Can delay the development of diabetic nephropathy, protect renal function, safe and effective, it is worth clinical promotion.